About BioElectronics Corporation BioElectronics Corporation (OTCPK: BIEL) is the maker of unique inexpensive, drug–free, anti-inflammatory patches for a broad range of unmet soft tissue medical needs. The patches have an embedded microchip and battery that deliver pulsed electromagnetic energy, a clinically proven and widely accepted anti-inflammatory and pain relief therapy that, previously, has only been possible to obtain from large, facility-based equipment. ActiPatch(tm) Makers of ActiPatch(tm) a drug-free, anti-inflammatory patch that resolves swelling BioElectronics has taken proven medical technologies and made them available to more people in new convenient, cost-effective, anti-inflammatory patches. By applying advanced microelectronic technology, BioElectronics has dramatically reduced the size and the cost of some well-established medical treatments. BioElectronics is the developer and marketer of ActiPatch(tm) medical devices which deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing of soft tissue injuries. A reduction of pain and swelling allows patients to return to normal activities much sooner. This patented technology is based on clinically proven, widely accepted PEMF therapy. The Company's ActiPatch is a drug-free, painless, pulsed energy patch. The ActiPatch has FDA clearance for the treatment of edema following blepharoplasty. We deliver a solution that: ~ Is drug-free ~ Reduces swelling and inflammation ~ Lasts 10 to 30 days, depending on model ~ Is comfortable ~ Provides continuous treatment ~ Is easy to use ~ Is safe ~ Is affordable ~ Provides localized, non-systemic treatment ~ Is lightweight Company Milestones BioElectronics has achieved the following early milestones: ~ United States Food and Drug Administration market clearance for treatment of edema (swelling) following blepharoplasty. ~ Canadian market approval for relief of pain in musculoskeletal complaints in both medical and over-the-counter. ~ CE Mark (European Common Market) Certification for the medical and retail over-the-counter markets for edema reduction, swelling, pain and inflammation. ~ ISO Certification. ~ 70+ domestic independent sales agents. ~ 20 International distributors and additional distribution agreements in negotiations or awaiting regulatory approvals. ~ A medical research partnership agreement with the Lahey Clinic, Burlington, Massachusetts, a leading teaching facility for Tuffs, Brown, and Harvard Medical Schools. ~ Use of ActiPatch by a number of professional sports teams and its Athletic Trainers Advisory Committee headed by Herm Schneider, Head Trainer of the Chicago White Soxs with members from leading professional athletic teams. ~ A solid intellectual property portfolio covering both the product design and the pulse signature. ~ A 3-year pipeline of new products for treatment of sports injuries, bone fractures, chronic injuries, chronic wounds, skin conditions, arthritis and post-operative care. Company News BioElectronics Corporation Recipient of Maryland Industrial Partnerships Award Pulsed Electromagnetic Therapy Acknowledged as Leading Biotechnology -- PR Newswire (Wed, Jan 16) BioElectronics Corporation Announces New Order; BioElectronics is Expanding into the Netherlands Market -- PR Newswire (Thu, Dec 6) BioElectronics Announces Expansion of Italian Market -- PR Newswire (Mon, Dec 3) BioElectronics Corporation Introduces Its New Heel Pain Product -- PR Newswire (Thu, Nov 15) ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan -- PR Newswire (Wed, Nov 14)

The NASD has published information on how to invest carefully at its web site.

Finally, investing is a very serious business and you should treat it as one. Never invest money you aren't willing to risk to loss. There are many pitfalls to investing, your continued learning in the stock market is your best advantage.

Forward-Looking Statements
This news release may contain forward-looking statements, which involve risks and uncertainties. Accordingly, no assurance can be given that the actual events and results will not be materially different than the anticipated results described in the forward-looking statement. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include the Company's success in its business and operations; the activities of new or existing competitors, the ability to attract and retain employees and strategic partners, the ability to leverage intangible assets, the ability to complete new projects at planned costs and on planned schedules and adoption of the Internet as a medium of commerce, communications and learning. Investors are also directed to consider other risks and uncertainties discussed in documents filed by the company with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All logo's, copyrights, trademarks, and corporate identities respectfully and rightful belong to all owners listed or replicated herewithin.